http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-737080-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
filingDate 1951-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1955-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-737080-A
titleOfInvention Hypnotic, sedative and anticonvulsant preparations and process for preparing same
abstract Ethinyl cyclohexanols of general formula <FORM:0737080/IV (b)/1> wherein Y is hydrogen or one or more methyl or ethyl groups are prepared by reacting cyclohexanone, or the appropriate alkyl derivative, with acetylene in the presence of an alkaline condensing agent such as sodium, sodamide, potassamide or potassium t.-amylate. With sodium as condensing agent, the reaction is conducted in liquid ammonia. Described is the preparation of (a) 1-ethinyl cyclohexanol-1; (b) 1 - ethinyl - 2 - methylcyclohexanol - 1; (c) 1-ethinyl-3-methylcyclohexanol; (d) 1-ethinyl-4-methylcyclohexanol; (e) 3,3,5-trimethyl-1-ethinylcyclohexanol-1; (f) 2,2-diethyl-1-ethinyl-cyclohexanol-1. Esters of the above cyclohexanols with acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids are prepared by reacting the ethinyl compound with the appropriate anhydride of the acid. Described is the preparation of (a) 3,3,5-trimethyl-1-ethinylpropionoxycyclohexane and (b) acid phthalate of 1 - ethinylcyclohexanol - 1. The ethinyl compounds and their esters are used in pharmaceutical compositions (see Group VI).ALSO:A hypnotic composition effective on human beings without toxic side reactions comprises an inert pharmaceutical carrier having incorporated therein a compound of formula <FORM:0737080/VI/1> where X is hydrogen or an acyl radacal and Y is hydrogen or one or more methyl or ethyl groups. The acyl covers both aliphatic and aromatic carboxylic acids which are pharmaceutically acceptable. Specified are the residues of acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids. The preparations are administered orally, parenterally or in the form of suppositories. Injections may be aqueous or oily solutions or suspensions containing dispersing agents such as polyethylene glycols. Oral medicaments are (a) soft gelatin capsules in which the active ingredient is dissolved in oil such as peanut, sesame or corn oil; (b) hard gelatin capsules in which the carbinol is absorbed on an inert absorbent such as magnesium oxide or carbonate, with or without the further addition of an oil; (c) tablets coated with resin; (d) elixir, in which the vehicle is an aqueous solution of propylene glycol or ethyl alcohol, glycerin and sucrose; (e) emulsion of oil, e.g. peanut, emulsifier, e.g. polyethylene glycol monostearate, and thickener, e.g. acacia, gelatin, dextrin, pectin, sodium alginate or agar agar. Suppositories have a basis of (a) white wax and cocoa butter, or (b) carbowax. Described is the preparation of (a) 1 - ethinyl cyclohexanol - 1; (b) 1 - ethinyl - 1 - acetoxycyclohexane; (c) 1 - ethinyl - 4 - methyl cyclohexanol - 1; (d) 1 - ethinyl - 3 - methyl-cyclohexanol - 1; (e) 1 - ethinyl - 2 - methyl-cyclohexanol - 1; (f) 3,3,5 - trimethyl - 1-ethinylcyclohexanol - 1; (g) 2,2 - diethyl - 1-ethinylcyclohexanol - 1; (h) 3,3,5 - trimethyl-1 - ethinylpropionoxycyclohexane; and (i) acid phthalate of 1 - ethinyl - cyclohexanol - 1 (see Group IV (b)).
priorityDate 1950-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID45679
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID138043
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448715498
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559508
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5102882
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID138043
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5988
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID311
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559553
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451412631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450984220
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527900
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489307
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93091914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454570538
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491805
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323524
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7967
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5360545
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474445
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87015
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID417430547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24762
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419548914
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416290180
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457740707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474094
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484158
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7966
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID181977
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID45679
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID243
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527785
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14792
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24533
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587756

Total number of triples: 70.